CDK and RAS-targeting drugs already exist, but in the setting of oncology, if it’s not curative, it’s not enough. As a former practicing oncologist, Onconova’s CEO Dr. Steven Fruchtman knows this and has spent his career at the bench, and now the boardroom, working to improve and provide such drugs for cancer patients. His CDK 4/6 drug, Narazaciclib, a drug with a much-improved toxicity profile relative to competitors, will commence a Phase 1/2a trial in endometrial cancer in Q1 2023. Onconova’s RAS inhibitor, Rigosertib, has shown activity in all flavors of KRAS mutations and is currently being tested in a Phase 2 investigation of checkpoint-resistant NSCLC patients. Tune in for a discussion of the next critical readouts.